Literature DB >> 8787820

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

D Blum-Degen1, T Müller, W Kuhn, M Gerlach, H Przuntek, P Riederer.   

Abstract

Interleukin-1 beta (IL-1 beta), interleukin-2 (IL-2), and interleukin-6 (IL-6) were measured in the cerebrospinal fluid (CSF) and plasma of 12 control subjects, 11 sporadic Alzheimer's disease (AD) and 22 de novo Parkinson's disease (PD) patients using high sensitivity enzyme-linked immunosorbent assays (ELISA). IL-1 beta and IL-6 contents were significantly elevated in the CSF of de novo PD and AD patients in comparison to the control group. In contrast, the plasma levels were not significantly affected. IL-2 contents in the CSF and plasma samples were unchanged in the three groups compared. Because the two cytokines IL-1 beta and IL-6 are known to play a key role in the interaction between the nervous and immune system, e.g. in the so-called acute phase response, our results support the involvement of immunological events in the complex process of neurodegeneration in AD and PD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8787820     DOI: 10.1016/0304-3940(95)12192-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  231 in total

1.  Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark.

Authors:  H H Nielsen; J Qiu; S Friis; L Wermuth; B Ritz
Journal:  Eur J Neurol       Date:  2012-01-17       Impact factor: 6.089

2.  Strategies for the protection of dopaminergic neurons against neurotoxicity.

Authors:  M Gerlach; K L Double; M B Youdim; P Riederer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 3.  Inflammation and adaptive immunity in Parkinson's disease.

Authors:  R Lee Mosley; Jessica A Hutter-Saunders; David K Stone; Howard E Gendelman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

4.  Role of the JAKs/STATs pathway in the intracellular calcium changes induced by interleukin-6 in hippocampal neurons.

Authors:  D I Orellana; R A Quintanilla; C Gonzalez-Billault; R B Maccioni
Journal:  Neurotox Res       Date:  2005-11       Impact factor: 3.911

5.  Cytokine production by a human microglial cell line: effects of beta-amyloid and alpha-melanocyte-stimulating hormone.

Authors:  Catharina Lindberg; Erik Hjorth; Claes Post; Bengt Winblad; Marianne Schultzberg
Journal:  Neurotox Res       Date:  2005-11       Impact factor: 3.911

Review 6.  The role of inflammatory processes in Alzheimer's disease.

Authors:  G Joseph Broussard; Jennifer Mytar; Rung-chi Li; Gloria J Klapstein
Journal:  Inflammopharmacology       Date:  2012-04-26       Impact factor: 4.473

7.  Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling.

Authors:  Mathew T Mizwicki; Milan Fiala; Larry Magpantay; Najib Aziz; James Sayre; Guanghao Liu; Avi Siani; Derrick Chan; Otoniel Martinez-Maza; Madhuri Chattopadhyay; Antonio La Cava
Journal:  Am J Neurodegener Dis       Date:  2012-11-21

Review 8.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 9.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

10.  Legumain Knockout Protects Against Aβ1-42-Induced AD-like Cognitive Deficits and Synaptic Plasticity Dysfunction Via Inhibiting Neuroinflammation Without Cleaving APP.

Authors:  Runwen Chen; Qiyue Zhang; Yuxing Yan; Yuying Zhang; Tao Zhang
Journal:  Mol Neurobiol       Date:  2020-11-21       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.